



Effect of age, breed size and enteropathogen infection on fecal immunoglobulin A concentrations in weaning puppies

Grellet A¹, Mila H², Feugier A¹, Lopes R³, Gruetzner N³, Suchodolski JS³, Steiner JM³, Chastant-Maillard S²

- 1- Royal Canin, 650 avenue de la Petite Camargue, 30470 Aimargues, France
- 2- UMR INRA/ENVT 1225 IHAP Ecole Nationale Vétérinaire de Toulouse, Toulouse, France
- 3- Gastrointestinal Laboratory, Texas A&M University, College Station, TX 77843-4474, USA.

Digestive health is a main concern for growth, morbidity and mortality in weaning puppies. Fecal immunoglobulin A (IgA) has been suggested as a useful noninvasive biomarker for mucosal immunity. The purpose of this study was to evaluate the effect of infection with enteropathogens on fecal IgA concentrations in puppies and that of physiological factors such as age and breed size.

282 puppies from 33 breeding kennels were included in the study. Puppies were between 5 and 14 weeks of age (mean±Standard Deviation (SD): 7.8 ± 1.5 weeks). Depending on the mean adult body weight of their respective breed, the puppies were divided into small (if mean adult body weight < 25 kg) or large (>25 kg) breed puppies. For each puppy, fecal consistency was evaluated using a 13-point scale and feces were collected for the evaluation of presence of fecal enteropathogens and fecal IgA concentrations. The presence of enteropathogens in fecal samples was evaluated by qPCR for canine parvovirus type 2 (CPV2), qRT-PCR for canine coronavirus (CCV), coproantigen quantification for Giardia (ProSpecT-Giardia, Remel), and McMaster flotation technique for other parasite eggs and oocysts. Fecal IgA concentrations were measured by an ELISA test. Statistical analyses were performed using SAS software. A linear mixed model (proc MIXED) with fecal IgA concentration as outcome was used to determine the following effects: enteropathogen infection, breed size, age, and fecal score. The respective influence of litter and breeding kennel as random effects was also determined. Data is presented as mean \pm SD.

Small breed dogs represented 27.3 % (77/282) of the total number of dogs included. At least one enteropathogen was identified in 76.2 % of puppies (214/281). Fecal IgA concentration was significantly influenced by fecal enteropathogens (p=0.037). Puppies infected with at least one enteropathogen had significantly lower fecal IgA concentrations than puppies without any enteropathogens ($5.0 \pm 4.4 \ \mu g/g \ vs. 6.9 \pm 5.5 \ \mu g/g$). Breed (p=0.029), but not age (p=0.082), influenced IgA concentration. Small breed puppies had significantly higher fecal IgA concentrations than large breed puppies ($6.8 \pm 4.8 \ \mu g/g \ vs. 5.0 \pm 4.7 \ \mu g/g$). No significant relationship between fecal IgA concentration and feces quality was evidenced (p=0.165).

This study suggests that fecal IgA concentration is a promising marker for subclinical infection by at least one enteropathogen and confirms that digestive physiology varies with the breed size. A link between lower digestive immunity and higher susceptibility to enteropathogen infection needs further investigation.

Effect of age, breed size and enteropathogen infection on fecal immunoglobulin A concentrations in weaning puppies

Grellet A¹, Mila H², Feugier A¹, Lopes R³, Gruetzner N³, Suchodolski JS³, Steiner JM³, Chastant-Maillard S²

TEXAS A&M



1: Royal Canin Research Center, Aimargues, France (aurelien.grellet@royalcanin.com) 2: Ecole Nationale Vétérinaire de Toulouse, Toulouse, France 3: Gastrointestinal Laboratory, Texas A&M University, College Station, USA






Introduction

Digestive health is a main concern for growth, morbidity and mortality in weaning puppies. Secretory immunoglobulin A (IgA) is the predominant immunoglobulin class present in secretions, protecting mucosal surfaces from infectious agents. Fecal IgA has been suggested as a noninvasive biomarker for mucosal immunity. The purpose of this study was to evaluate the effect of enteropathogens infection on fecal IgA concentrations in puppies and that of physiological factors such as age and breed size.

Materials and methods

260 puppies from 32 breeding kennels were included in the study. Only puppies with a normal clinical examination were included (puppies with clinical signs of prostration, dehydration and/or anorexia were excluded from this study). Depending on the mean adult body weight of their respective breed, puppies were divided into small (mean adult body weight < 25 kg) or large (>25 kg) breed puppies. For each puppy, fecal consistency was evaluated using a 13-point scale adapted for fecal scoring in puppies [1]. Feces were collected to evaluate presence of fecal enteropathogens and to assay fecal IgA concentrations. Detection of enteropathogens was perfomed by qPCR for canine parvovirus type 2 (CPV2), qRT-PCR for canine coronavirus (CCV), coproantigen quantification for *Giardia duodenalis* (ProSpecT-Giardia, Remel), and McMaster flotation technique for conventional coproscopy. Fecal IgA concentrations were measured by an ELISA test as previously described [2].

Statistical analysis was performed using R software (R package version 1.1-7 Vienna, Austria). A linear mixed model (lme4) was used to evaluate effect of enteropathogens infection and breed size, as fixed effects, on IgA concentrations. Age, fecal score and litter nested in breeding kennel were modeled as random effects. A logarithmic transformation of this outcome was required to obtain a normal distribution of the residuals. Data are presented as median and range.



Conclusion

This study underlines that fecal IgA concentrations vary markedly depending of physiologic and pathologic factors like breed size and parasite infections. These factors need to be considered when fecal IgA is used for evaluation of intestinal immunity. Further investigation is necessary in order to understand the relationship between fecal IgA and intestinal pathogens.

[1] Grellet A. et al. Prev. Vet. Med. 2012 106 (3-4): 315-323; [2] Tress U. et al. Am. J. Vet. Res. 67, 1756-1759; [3] Peters IR. et al. Clin Vaccine Immunol. 2004,11 (5): 841-848; [4] Langford TD. et al. Infect. Immun. 2002; 70 (1): 11-18